389 related articles for article (PubMed ID: 27394428)
41. Management of Osteoporosis in Chronic Kidney Disease.
Nitta K; Yajima A; Tsuchiya K
Intern Med; 2017 Dec; 56(24):3271-3276. PubMed ID: 29021477
[TBL] [Abstract][Full Text] [Related]
42. [Denosumab in clinical practice : beware before, during and after].
Lamy O; Gonzalez-Rodriguez E; Stoll D; Aubry-Rozier B
Rev Med Suisse; 2017 Apr; 13(559):863-866. PubMed ID: 28727345
[TBL] [Abstract][Full Text] [Related]
43. Case report: Recurrent severe hypocalcemia secondary to denosumab in a patient with chronic kidney disease.
Correia M; Pereira P; Ferreira CC; Cerqueira M; Almeida DE
Int J Rheum Dis; 2024 Jun; 27(6):e15211. PubMed ID: 38831530
[No Abstract] [Full Text] [Related]
44. Denosumab-associated hypocalcemia: Does gender play a role?
Diker-Cohen T; Amitai O; Shochat T; Shimon I; Tsvetov G
Maturitas; 2020 Dec; 142():17-23. PubMed ID: 33158483
[TBL] [Abstract][Full Text] [Related]
45. Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease.
Ueki K; Yamada S; Tsuchimoto A; Tokumoto M; Kumano T; Kitazono T; Tsuruya K
Intern Med; 2015; 54(20):2637-42. PubMed ID: 26466702
[TBL] [Abstract][Full Text] [Related]
46. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
Yerram P; Kansagra S; Abdelghany O
J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
[TBL] [Abstract][Full Text] [Related]
47. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD
J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870
[TBL] [Abstract][Full Text] [Related]
48. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
Dusilova Sulkova S; Horacek J; Safranek R; Gorun P; Viklicky O; Palicka V
Acta Medica (Hradec Kralove); 2014; 57(1):30-3. PubMed ID: 25006661
[TBL] [Abstract][Full Text] [Related]
49. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
Watkins KR; Rogers JE; Atkinson B
Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
[TBL] [Abstract][Full Text] [Related]
50. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
51. Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
Iizumi S; Shimoi T; Nishikawa T; Kitano A; Sasada S; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Intern Med; 2017 Nov; 56(21):2879-2882. PubMed ID: 28943574
[TBL] [Abstract][Full Text] [Related]
52. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
53. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
54. Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency.
Gronskaya S; Belaya Z; Rozhinskaya L; Mamedova E; Vorontsova M; Solodovnikov A; Golounina O; Melnichenko G
Endocrine; 2023 Aug; 81(2):368-378. PubMed ID: 37133642
[TBL] [Abstract][Full Text] [Related]
55. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
[TBL] [Abstract][Full Text] [Related]
56. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
57. Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients.
Hori M; Yasuda K; Takahashi H; Kondo C; Shirasawa Y; Ishimaru Y; Sekiya Y; Morozumi K; Maruyama S
Sci Rep; 2022 May; 12(1):7781. PubMed ID: 35546172
[TBL] [Abstract][Full Text] [Related]
58. Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia.
Lambe G; Malvathu R; Thomas HM; Graves A
Nephrology (Carlton); 2015 Aug; 20(8):583-4. PubMed ID: 26194986
[No Abstract] [Full Text] [Related]
59. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
[TBL] [Abstract][Full Text] [Related]
60. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
